FOXFIRE: First line treatment of patients with liver metastatic colorectal cancer

An open-label randomised phase III trial of 5-fluorocil, OXaliplatin and Folinic acid +/- Interventional Radio-Embolisation as first line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer.

This is a Phase III randomized trial comparing the addition of liver-targeted brachytherapy (radioembolisation) to systemic chemotherapy compared with current standard treatment in patients with liver metastatic colorectal cancer.  HERC will undertake a cost-effectiveness analysis alongside this Phase III trial.  Detailed data on resource utilization associated with health care (primary and secondary care) and informal care are being collected alongside the trial.  Data on patient costs and change in employments status over the time-horizon of the trial are also being routinely documented.  Health-related quality of life is being routinely collected using the EORTC QLQ-C30/QLQ-LCM21 and the EQ-5D instruments.